Economics ❯Healthcare Costs ❯Cost-Benefit Analysis ❯Financial Burden of Illness

Impact on Families

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

Lecanemab, the first drug to slow Alzheimer's progression, approved by UK regulator but deemed too expensive for NHS use.